Both AstraZeneca/Bristol Diabetes Drugs Should Meet FDA Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca execs maintain during earnings call that clinical trial programs for dapagliflozin and saxagliptin satisfy new regulatory requirements.